MLYS vs NVS
MLYS: A clinical-stage biopharmaceutical company developing lorundrostat, a novel aldosterone synthase inhibitor targeting hypertension and cardiorenal diseases. NVS: Global pharmaceutical and biotechnology company pioneering disease-modifying treatments across oncology, immunology, neuroscience, and rare genetic diseases.
Side-by-side fundamentals
| Metric | MLYS | NVS | Edge |
|---|---|---|---|
| Price as of 2026-08-21 close | $25.65 | $158.86 | |
| Market cap as of 2026-08-24 | $2.3B | $227.4B | |
| P/E as of 2026-08-24 | n/a | 21.95 | |
| PEG as of 2026-08-24 | -0.32 | 3.66 | MLYS lower |
| Net margin as of 2026-08-24 | n/a | +22.5% | |
| Gross margin as of 2026-08-24 | n/a | +75.0% | |
| Operating margin as of 2026-08-24 | n/a | +29.9% | |
| ROE as of 2026-08-24 | -27.9% | +29.9% | NVS higher |
| ROA as of 2026-08-24 | -27.0% | +11.1% | NVS higher |
| Debt / equity as of 2026-08-24 | 0.00 | 1.18 | MLYS lower |
| Revenue growth (YoY) as of 2026-08-24 | n/a | +3.3% | |
| Dividend yield as of 2026-08-24 | n/a | +3.7% | |
| Beta as of 2026-08-24 | 0.61 | 1.17 | |
| 1-year return as of 2026-08-21 close | +75.6% | +25.3% | MLYS higher |
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.